Limin Zhang

Key Laboratory Of Organ Transplantation, NHC Key Laboratory Of Organ Transplantation, Key Laboratory Of Organ Transplantation
Wuhan, 430030, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Attenuation of Pulmonary Fibrosis by the MyD88 Inhibitor TJ-M2010-5 Through Autophagy Induction in Mice.

Attenuation of Pulmonary Fibrosis by the MyD88 Inhibitor TJ-M2010-5 Through Autophagy Induction in Mice.

Journal: Biomedicines

Published: July 31, 2025

Case Report: Successful transplantation of a living donor kidney with five renal arteries procured via laparoscopy and back-table vascular reconstruction using the recipient's internal iliac artery.

Case Report: Successful transplantation of a living donor kidney with five renal arteries procured via laparoscopy and back-table vascular reconstruction using the recipient's internal iliac artery.

Journal: Frontiers in medicine

Published: January 03, 2025

Whole-liver intensity-modulated radiation therapy as a rescue therapy for acute graft-versus-host disease after liver transplantation.

Whole-liver intensity-modulated radiation therapy as a rescue therapy for acute graft-versus-host disease after liver transplantation.

Journal: Chinese medical journal

Published: June 20, 2024

Treatment of a MyD88 inhibitor alleviates rejection and inflammation in xenotransplantation by inhibiting dendritic cells activation and trained immunity in macrophages.

Treatment of a MyD88 inhibitor alleviates rejection and inflammation in xenotransplantation by inhibiting dendritic cells activation and trained immunity in macrophages.

Journal: International immunopharmacology

Published: December 09, 2023

Porcine anti-human lymphocyte immunoglobulin depletes the lymphocyte population to promote successful kidney transplantation.

Porcine anti-human lymphocyte immunoglobulin depletes the lymphocyte population to promote successful kidney transplantation.

Journal: Frontiers in immunology

Published: December 15, 2022

TJ-M2010-5, a novel CNS drug candidate, attenuates acute cerebral ischemia-reperfusion injury through the MyD88/NF-κB and ERK pathway.

TJ-M2010-5, a novel CNS drug candidate, attenuates acute cerebral ischemia-reperfusion injury through the MyD88/NF-κB and ERK pathway.

Journal: Frontiers in pharmacology

Published: October 26, 2022

Indirect and direct estimation of pharmacokinetic parameters in dynamic diffuse fluorescence tomography by adaptive extended Kalman filtering.

Indirect and direct estimation of pharmacokinetic parameters in dynamic diffuse fluorescence tomography by adaptive extended Kalman filtering.

Journal: Applied optics

Published: October 18, 2022

The Novel MyD88 Inhibitor TJ-M2010-5 Protects Against Hepatic Ischemia-reperfusion Injury by Suppressing Pyroptosis in Mice.

The Novel MyD88 Inhibitor TJ-M2010-5 Protects Against Hepatic Ischemia-reperfusion Injury by Suppressing Pyroptosis in Mice.

Journal: Transplantation

Published: October 13, 2022

TJ-M2010-5, A self-developed MyD88 inhibitor, attenuates liver fibrosis by inhibiting the NF-κB pathway.

TJ-M2010-5, A self-developed MyD88 inhibitor, attenuates liver fibrosis by inhibiting the NF-κB pathway.

Journal: Chemico-biological interactions

Published: October 28, 2021

Correction to: Depletion of acetate-producing bacteria from the gut microbiota facilitates cognitive impairment through the gut-brain neural mechanism in diabetic mice.

Correction to: Depletion of acetate-producing bacteria from the gut microbiota facilitates cognitive impairment through the gut-brain neural mechanism in diabetic mice.

Journal: Microbiome

Published: July 29, 2021

Depletion of acetate-producing bacteria from the gut microbiota facilitates cognitive impairment through the gut-brain neural mechanism in diabetic mice.

Depletion of acetate-producing bacteria from the gut microbiota facilitates cognitive impairment through the gut-brain neural mechanism in diabetic mice.

Journal: Microbiome

Published: January 27, 2021

TJ-M2010-5, a novel MyD88 inhibitor, corrects R848-induced lupus-like immune disorders of B cells in vitro.

TJ-M2010-5, a novel MyD88 inhibitor, corrects R848-induced lupus-like immune disorders of B cells in vitro.

Journal: International immunopharmacology

Published: April 09, 2020

Showing 1-12 of 33

Last Updated: 09/26/2026